- 2023.10.31
- Patents, Articles & Conferences Announcement of presentation at the 43rd Annual Scientific Meeting of the Japanese Society of Ocular Pharmacology (November 11 – 12, 2023)
- 2023.10.3
- Information Science Impact magazine published an article about the treatment for Hunner-type interstitial cystitis using TAGCyx’s aptamer, TAGX-0003.
- 2023.9.15
- Patents, Articles & Conferences Announcement of presentation at the 44th Annual Meeting of the Japanese Society for Apheresis (October 20 – 22, 2023)
- 2023.9.13
- Event We will have a booth V-36 at Japan Healthcare Venture Summit 2023 on Oct 11st-13rd
- 2023.5.29
- Information Announcing the renovating of TAGCyx website
- 2023.4.18
- Patents, Articles & Conferences We will be presenting Apheresis project at ISFA 2023 (June 1st – 3rd at Berlin）
- 2023.3.30
- Patents, Articles & Conferences We will be presenting Hunner-type Interstitial Cystitis project at AUA annual meeting 2023 (April 28th-May 1st at Chicago）
- 2022.12.23
- Event TAGCyx will be attending 41st Annual J.P. Morgan Healthcare Conference
- 2022.10.31
- Patents, Articles & Conferences Announcement of presentation at the 43rd Annual Meeting of the Japanese Society for Apheresis (November 12, 2022)
- 2022.9.8
- News Release CAGE Bio and TAGCyx announced execution of a license agreement for development and commercialization of TAGX-0003 for the treatment of immunodermatology diseases mediated by the IFN-γ pathway
- 2022.7.13
- Event ‘The 3rd Aptamer Seminar in Tokyo ~virtual meeting~’ will be held on September 2, 2022.
- 2022.3.23
- News Release TAGCyx secured a grant funding from ‘Support Program for Orphan drug prior to the Designation’ of Japan Agency for Medical Research and Development (AMED).